Seattle-based AI drug discovery startup Talus Biosciences raised USD 11.2 million in a seed+ funding round led by Two Bear Capital. Other participants included WRF Capital, NFX, and YC Continuity Fund.
The funding will advance Talus Bio's therapeutic programs, including Brachyury-driven cancers and an undruggable transcription factor implicated in prostate cancer. It will also accelerate the expansion of the company's proprietary MARMOT platform.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.